Non Small Cell Lung Cancer Clinical Trials in Albany, New York

7 studies are recruiting for non small cell lung cancer in Albany, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

   Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prev…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology, P.C. ( Site 9000), Albany, New York

   Locations

   93 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07513376 on ClinicalTrials.gov

2. A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

   Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderas…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology, P.C. ( Site 0119), Albany, New York

   Locations

   211 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07190248 on ClinicalTrials.gov

3. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

   Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology P.C ( Site 9000), Albany, New York

   Locations

   73 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07554339 on ClinicalTrials.gov

4. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

   This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology, P.C. ( Site 0132), Albany, New York

   Locations

   225 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06345729 on ClinicalTrials.gov

5. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

   The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology, P.C. ( Site 4012), Albany, New York

   Locations

   229 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06077760 on ClinicalTrials.gov

6. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Oncology Hematology, Albany, New York

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

7. GEMINI-NSCLC: NSCLC Biomarker Study

   GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   New York Oncology Hematology, Albany, New York

   Locations

   58 in total

   Run by

   Tempus AI

   See if you can join NCT05236114 on ClinicalTrials.gov